2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-000325-26-FR (EUCTR) | 29/04/2021 | 19/02/2021 | Phase 2 safety and tolerability study using ANX005 for ALS | Phase 2a Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Intravenous ANX005 in Subjects with Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Scelrosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: ANX005 INN or Proposed INN: ANX005 Other descriptive name: IMMUNOGLOBULIN G | Annexon Biosciences | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 25 | Phase 2 | United States;France;Canada | ||
| 2 | EUCTR2012-003349-13-DE (EUCTR) | 15/01/2013 | 12/12/2012 | A Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (ALS) | Study NOG112264, a Phase II Study of Ozanezumab(GSK1223249) versus Placebo in the Treatment of AmyotrophicLateral Sclerosis - Ozanezumab Phase II study in patients with ALS | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ozanezumab Product Code: GSK1223249 INN or Proposed INN: Ozanezumab Other descriptive name: Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy chain), disulfide with human Mus musculus monoclonal light chain, dimer | GlaxoSmithKline Research and Development Limited | NULL | Not Recruiting | Female: yes Male: yes | 294 | Phase 2 | France;United States;Canada;Belgium;Australia;Netherlands;Germany;United Kingdom;Italy;Japan;Korea, Republic of | ||
| 3 | EUCTR2012-003349-13-NL (EUCTR) | 15/01/2013 | 12/11/2012 | A Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (ALS) | Study NOG112264, a Phase II Study of Ozanezumab(GSK1223249) versus Placebo in the Treatment of AmyotrophicLateral Sclerosis - Ozanezumab Phase II study in patients with ALS | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ozanezumab Product Code: GSK1223249 INN or Proposed INN: Ozanezumab Other descriptive name: Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy chain), disulfide with human Mus musculus monoclonal light chain, dimer | GlaxoSmithKline Research and Development Limited | NULL | Not Recruiting | Female: yes Male: yes | 294 | Phase 2 | France;United States;Canada;Belgium;Australia;Germany;Netherlands;United Kingdom;Italy;Japan;Korea, Republic of | ||
| 4 | EUCTR2012-003349-13-GB (EUCTR) | 19/12/2012 | 18/12/2012 | A Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (ALS) | Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis - Ozanezumab Phase II study in patients with ALS | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ozanezumab Product Code: GSK1223249 INN or Proposed INN: Ozanezumab Other descriptive name: Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy chain), disulfide with human Mus musculus monoclonal light chain, dimer | GlaxoSmithKline Research and Development Limited | NULL | Not Recruiting | Female: yes Male: yes | 294 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | France;United States;Canada;Belgium;Australia;Germany;Netherlands;Italy;Japan;United Kingdom;Korea, Republic of | ||
| 5 | EUCTR2012-003349-13-FR (EUCTR) | 17/12/2012 | 20/06/2013 | A Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (ALS) | Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis - Ozanezumab Phase II study in patients with ALS | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ozanezumab Product Code: GSK1223249 INN or Proposed INN: Ozanezumab Other descriptive name: Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy chain), disulfide with human Mus musculus monoclonal light chain, dimer | GlaxoSmithKline Research and Development Limited | NULL | Not Recruiting | Female: yes Male: yes | 294 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;France;Canada;Belgium;Australia;Germany;Netherlands;United Kingdom;Italy;Japan;Korea, Republic of | ||
| 6 | EUCTR2012-003349-13-BE (EUCTR) | 06/12/2012 | 02/10/2012 | A Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (ALS) | Study NOG112264, a Phase II Study of Ozanezumab(GSK1223249) versus Placebo in the Treatment of AmyotrophicLateral Sclerosis - Ozanezumab Phase II study in patients with ALS | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 15.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ozanezumab Product Code: GSK1223249 INN or Proposed INN: Ozanezumab Other descriptive name: Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy chain), disulfide with human Mus musculus monoclonal light chain, dimer | GlaxoSmithKline Research and Development Limited | NULL | Not Recruiting | Female: yes Male: yes | 294 | Phase 2 | Australia;Germany;Netherlands;United Kingdom;France;United States;Canada;Belgium;Italy;Japan;Korea, Republic of | ||
| 7 | EUCTR2012-003349-13-IT (EUCTR) | 03/12/2012 | 11/12/2012 | a Phase II Study of Ozanezumab(GSK1223249) versus Placebo in the Treatment of AmyotrophicLateral Sclerosis | Study NOG112264, a Phase II Study of Ozanezumab(GSK1223249) versus Placebo in the Treatment of AmyotrophicLateral Sclerosis - Ozanezumab Phase II study in patients with ALS | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Ozanezumab Product Code: GSK1223249 Other descriptive name: Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy | GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD. | NULL | Not Recruiting | Female: yes Male: yes | 294 | Phase 2 | France;United States;Canada;Belgium;Australia;Germany;Netherlands;United Kingdom;Japan;Italy;Korea, Republic of |